(5-bromo-thiazol-2-yl)-(3-methylsulfanyl-phenyl)-amine | 923947-19-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (5-bromo-thiazol-2-yl)-(3-methylsulfanyl-phenyl)-amine
• 英文别名: 5-bromo-N-[3-(methylsulfanyl)phenyl]-1,3-thiazol-2-amine；5-bromo-N-(3-methylsulfanylphenyl)-1,3-thiazol-2-amine
• CAS: 923947-19-7
• 化学式: C₁₀H₉BrN₂S₂
• 分子量: 301.231
• InChiKey: LZXFIXLCRDSHDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  78.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Wan Yongqin

  公开号：US20080227783A1

  公开（公告）日：2008-09-18

  The invention provides 5-substituted thiazol-2-yl amino compounds of Formula (I): pharmaceutical compositions comprising such compounds and the use of such compounds for the treatment or prevention of diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Ab 1, Aurora-A, Ber-Ab1, Bmx, CDKI/cyclinB, CHK2, Fes, FGFR3, Flt3, GSK3β, JNK1α1, Lck, MKK4 and TrkB kinases.

  本发明提供了式(I)的5-取代噻唑-2-基氨基化合物，以及包含这种化合物的制药组合物，并将这种化合物用于治疗或预防与异常或失调的激酶活性相关的疾病或障碍，特别是涉及Ab 1、Aurora-A、Ber-Ab1、Bmx、CDKI/cyclinB、CHK2、Fes、FGFR3、Flt3、GSK3β、JNK1α1、Lck、MKK4和TrkB激酶异常激活的疾病或障碍。
• 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP1912959A2

  公开（公告）日：2008-04-23
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE KINASE DE PROTÉINE
  申请人：IRM LLC

  公开号：WO2007016228A2

  公开（公告）日：2007-02-08

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Aurora-A, Bcr-Abl, Bmx, CDK1/cyclinB, CHK2, Fes, FGFR3, Flt3, GSK3ß , JNK1a1, Lck, MKK4 and TrkB kinases.
  [FR] La présente invention concerne une nouvelle classe de composés, des compositions pharmaceutiques comprenant de tels composés ainsi que des procédés d'utilisation de tels composés pour traiter les maladies ou les troubles associés à une activité kinase anormale ou dérégulée, en particulier les maladies ou les troubles impliquant une activation anormale des kinases Abl, Aurora-A, Bcr-Abl, Bmx, CDK1/cyclineB, CHK2, Fes, FGFR3, Flt3, GSK3ß, JNK1a1, Lck, MKK4 et TrkB.